

Annual Report 2009 Q-Med AB (publ)

Q-Med's Annual Report can be downloaded from the company's website at www.q-med.com as from today.

The Annual Report will be sent to Q-Med shareholders who have actively requested this and to other stakeholders during the week commencing April 12.

Queries should be addressed to:

Karin Falck, PR & Corporate Communications
Tel: +46 70 974 9015

*Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, **NASHA**[™], for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane**[®] for filling lines and folds, contouring and creating volume in the face, **Macrolane**[™] for body contouring, **Durolane**[™] for the treatment of osteoarthritis of the hip and knee joints, **Deflux**[®] for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta**[™] for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.*
